<SEC-DOCUMENT>0001493152-26-036856.txt : 20260810
<SEC-HEADER>0001493152-26-036856.hdr.sgml : 20260810
<ACCEPTANCE-DATETIME>20260810160518
ACCESSION NUMBER:		0001493152-26-036856
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20260805
FILED AS OF DATE:		20260810
DATE AS OF CHANGE:		20260810

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Morrison James William
		CENTRAL INDEX KEY:			0002137380
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38306
		FILM NUMBER:		261258341

	MAIL ADDRESS:	
		STREET 1:		9605 MEDICAL CENTER DRIVE
		STREET 2:		SUITE 270
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Ensysce Biosciences, Inc.
		CENTRAL INDEX KEY:			0001716947
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				822755287
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		7946 IVANHOE AVENUE
		STREET 2:		SUITE 201
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037
		BUSINESS PHONE:		(858) 263-4196

	MAIL ADDRESS:	
		STREET 1:		7946 IVANHOE AVENUE
		STREET 2:		SUITE 201
		CITY:			LA JOLLA
		STATE:			CA
		ZIP:			92037

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Leisure Acquisition Corp.
		DATE OF NAME CHANGE:	20170913
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>ownership.xml
<DESCRIPTION>3
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0607</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2026-08-05</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001716947</issuerCik>
        <issuerName>Ensysce Biosciences, Inc.</issuerName>
        <issuerTradingSymbol>ENSC</issuerTradingSymbol>
        <issuerForeignTradingSymbol></issuerForeignTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0002137380</rptOwnerCik>
            <rptOwnerName>Morrison James William</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerNonUSAddressFlag>false</rptOwnerNonUSAddressFlag>
            <rptOwnerStreet1>C/O ENSYSCE BIOSCIENCES, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>7946 IVANHOE AVENUE, SUITE 201</rptOwnerStreet2>
            <rptOwnerCity>LA JOLLA</rptOwnerCity>
            <rptOwnerState>CA</rptOwnerState>
            <rptOwnerZipCode>92037</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>1</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle>President</officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <derivativeTable>
        <derivativeHolding>
            <securityTitle>
                <value>Series C Non-Voting Convertible Preferred Stock</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <footnoteId id="F1"/>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <footnoteId id="F1"/>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>154821000</value>
                    <footnoteId id="F2"/>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>By Belgarion Ventures Ltd.</value>
                    <footnoteId id="F3"/>
                </natureOfOwnership>
            </ownershipNature>
        </derivativeHolding>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">Each share of Series C Non-Voting Convertible Preferred Stock will automatically convert into 1,000 shares of Common Stock upon approval of such conversion by the Issuer's stockholders in accordance with the rules of The Nasdaq Stock Market LLC, subject to a beneficial ownership limitation established by the holder of between 4.9% and 19.9% of the outstanding Common Stock. The Series C Non-Voting Convertible Preferred Stock does not have a conversion price and has no expiration date.</footnote>
        <footnote id="F2">The reported shares of Common Stock underlie 154,821 shares of Series C Non-Voting Convertible Preferred Stock received by Belgarion Ventures Ltd. in exchange for 6,500,000 shares of common stock of Cy Biopharma, Inc. (&quot;Cy&quot;) in connection with the Issuer's merger (the &quot;Merger&quot;) with Cy , pursuant to the Agreement and Plan of Merger (the &quot;Merger Agreement&quot;), dated as of August 5, 2026, by and among the Issuer, Cy, PHRMA Merger Sub I, Inc. and PHRMA Merger Sub II, Inc. Under the terms of the Merger Agreement, at the effective time of the Merger, each outstanding share of Cy common stock was converted automatically into the right to receive 0.0238187 shares of Series C Non-Voting Convertible Preferred Stock, representing 23.8187 shares of Common Stock on an as-converted basis.</footnote>
        <footnote id="F3">These securities are held of record by Belgarion Ventures Ltd. The Reporting Person is a director of, and holds a controlling interest in, Belgarion Ventures Ltd., and may be deemed to have sole voting and dispositive power over the securities held by it. The Reporting Person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ James William Morrison</signatureName>
        <signatureDate>2026-08-10</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
